Budget office: $177B in added costs from Trump drug plan

WASHINGTON (AP) — The Trump administration's plan to ease the financial hit of prescription drugs prices for Medicare beneficiaries will cost taxpayers another $177 billion over 10 years, congressional budget experts said on Thursday.

The estimates from the nonpartisan Congressional Budget Office could affect prospects for one of the administration's centerpiece proposals to make prescription drugs more affordable for patients. President Donald Trump and leading lawmakers of both parties want to act before the 2020 elections.

Under the Trump administration's proposed regulation, drugmaker rebates now paid to insurance companies and their middlemen would instead go directly to seniors in Medicare's Part D program when they fill their prescriptions.

Rebates are a largely unseen part of the complex world of drug pricing.

Drugmakers pay the money in part to get favorable placement for their medications among a health plan's covered drugs. Insurers say rebates help keep premiums in check. But when patients go to fill their prescriptions, their copays are usually calculated based on the list price of medications, not the discounted price after rebates.

Awarding the discounts directly to patients would reduce copays for many Medicare beneficiaries.

But CBO concluded that drug companies are unlikely to lower list prices across the board in response to the administration plan. Instead, they would reimburse pharmacies for discounts provided to individual seniors as they fill their prescriptions.

The budget office said the bottom line would be an increase in premiums, which are split between the government and seniors. Because the government subsidizes about 75% of the cost, that would add $170 billion to program spending from 2020-2029. Medicaid spending would also increase by $7 billion.

"Some beneficiaries would pay lower prices on their prescription drugs, and for some beneficiaries, those reductions would be greater than their premium increases," the CBO analysis said. "For other beneficiaries — namely those who use few drugs or drugs without significant rebates — the premium increase would outweigh the price reductions."

There was no immediate reaction from the Trump administration. The rebate regulation is scheduled to take effect next year, and does not require direct congressional approval. However, congressional opposition could complicate things for the administration.

Leading House Democrats have been skeptical of the administration's approach, instead arguing that Medicare should negotiate prices directly with drug companies.

___

Online:

CBO analysis: https://tinyurl.com/yy3tz2uu